Trials / Unknown
UnknownNCT04239170
Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma
An Open-lable, Single Arm, Phase 2 Study of Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Will Receive ASCT
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single arm, Phase 2 study to evaluate efficacy and safety of PD1 inhibitor Camrelizumab(SHR-1210) combined with Gemox in patients with relapsed and refractory hodgkin lymphoma who will receive ASCT.Efficacy will be assessed according to 2014 Lugano criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab(SHR-1210) | Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2020-01-23
- Last updated
- 2020-01-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04239170. Inclusion in this directory is not an endorsement.